Previous 10 | Next 10 |
SILVER SPRING, Md., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company...
Start Time: 16:30 End Time: 17:10 Aziyo Biologics, Inc. (AZYO) Q2 2021 Earnings Conference Call August 09, 2021, 16:30 PM ET Company Participants Ronald Lloyd - President and CEO Matthew Ferguson - CFO Leigh Salvo - IR, Gilmartin Group LLC Conference Call Participants Matthew O’Brien -...
SILVER SPRING, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial res...
SILVER SPRING, Md., July 26, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plan...
SILVER SPRING, Md., June 07, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) on June 2, 2021 issued a voluntary recall pertaining to a single donor lot of its FiberCel Fiber Viable Bone Matrix, a bone repair product made from human tissue that is used in various orthopedic and...
The following slide deck was published by Aziyo Biologics, Inc. in conjunction with this event. For further details see: Aziyo Biologics (AZYO) Investor Presentation - Slideshow
Aziyo Biologics, Inc. (AZYO) Q1 2021 Results Earnings Conference Call May 4, 2021, 04:30 PM ET Company Participants Leigh Salvo - Investor Relations, Gilmartin Group LLC Ronald Lloyd - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participant...
Aziyo Biologics (AZYO): Q1 GAAP EPS of -$0.50 beats by $0.04.Revenue of $12.9M beats by $1.79M.Press Release For further details see: Aziyo Biologics EPS beats by $0.04, beats on revenue
SILVER SPRING, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial resu...
Aziyo Biologics (AZYO) announces the initiation of an observational study to provide insight into the clinical profiles, procedural details and post-implant outcomes in patients receiving Aziyo’s CanGaroo Envelope or no envelope during initial (de novo) cardiac implantable electro...
News, Short Squeeze, Breakout and More Instantly...
Aziyo Biologics Inc. Company Name:
AZYO Stock Symbol:
NASDAQ Market:
– Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding ref...
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”...
Negotiating multiple LOIs to divest Orthopedic business CanGaroo ® RM 510(k) resubmission to the FDA remains on track SimpliDerm ® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular ...